FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
This article was originally published in The Tan Sheet
Executive Summary
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare